Lohrmann, Florens
Efstratiou, Androulla
Sørensen, Uffe B. Skov
Creti, Roberta
Decheva, Antoaneta
Křížová, Pavla
Kozáková, Jana
Rodriguez-Granger, Javier
De La Rosa Fraile, Manuel
Margarit, Immaculada
Rinaudo, Daniela
Maione, Domenico
Telford, John
Orefici, Graziella
Kilian, Mogens
Afshar, Baharak
Melin, Pierrette
Berner, Reinhard
Hufnagel, Markus
Kunze, Mirjam
,
Poulsen, K
Karstens, L
Baldassarri, L
Rigat, F
Berardi, A
Imperi, M
Funding for this research was provided by:
Seventh Framework Programme (200481, 200481, 200481, 200481, 200481, 200481, 200481, 200481, 200481, 200481, 200481, 200481, 200481, 200481, 200481, 200481, 200481, 200481, 200481)
GlaxoSmithKline Biologicals SA
Universitätsklinikum Freiburg
Article History
Received: 24 July 2024
Accepted: 20 August 2024
First Online: 8 September 2024
Declarations
:
: Financial interests: Margarit I, Maione D and Rinaudo D are employees of the GSK group of companies and hold shares in the GSK group of companies. Margarit I, Maione D and Rinaudo D are listed as inventor on patents owned by the GSK group of companies. Uffe B. Skov Sørensen and Mogens Kilian received personal consultancy fees from Suzhou VACMICRO Biotech Co., Ltd. Non-financial interests: Markus Hufnagel has been invited by Novartis to an advisory board meeting on juvenile idiopathic arthritis. Pierrette Melin has provided one scientific consultation for GSK vaccines. All other authors have no financial or non-financial interests to disclose.
: The study was approved by local ethics committees of each participating institution, and informed consent for study participation has been obtained from the legal caregivers. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.